US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment
I'm PortAI, I can summarize articles.
The U.S. FDA has approved Vertex Pharmaceuticals' new triple combination treatment for cystic fibrosis, branded Alyftrek, for patients aged 6 and older. This approval enhances Vertex's position in the cystic fibrosis market, where it has already made significant advancements with its previous drug, Trikafta. Cystic fibrosis affects around 40,000 individuals in the U.S., leading to severe respiratory issues. The company has not yet disclosed pricing or availability details for Alyftrek.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments